Find Academic Supervisors

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +7 more

Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.

• Biocatalysis
• Bioremediation
• Bioprocess engineering
• +15 more

Kora DeBeck is a Distinguished Professor of Substance Use and Drug Policy in the School of Public Policy at Simon Fraser University, a CIHR Applied Public Health Chair, and Dorothy Killam Fellow. She is also a Research Scientist with the BC Centre on Substance Use and Principal Investigator of the At-Risk Youth Study (ARYS), a longitudinal cohort tracking over 1,200 street-involved youth. Her research focuses on substance use policy, health services for marginalized populations, and the structural drivers of drug-related harms. She has published over 200 peer-reviewed articles challenging ineffective drug enforcement models and advocating for policy reforms. Recent publications analyze trends in opioid use, harm reduction during the COVID-19 pandemic, drug decriminalization, and youth-focused interventions. Her work consistently addresses social inequities through data-driven approaches to the toxic drug crisis. CIHR Applied Public Health Chair Dorothy Killam Fellow Michael Smith Health Research BC Scholar Award Distinguished SFU Professorship She has secured over $50 million in research funding, including $21M as principal investigator for ARYS. Her lab collaborates with healthcare providers, community organizations, and policymakers to translate research into practice.

• Substance Use
• Drug Policy
• Health Policy
• +3 more

David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.

• Bioorganic Chemistry
• Chemical Biology
• Glycobiology
• +3 more

Houman Savoji is an Associate Professor in the Department of Pharmacology and Physiology at the Faculty of Medicine, University of Montreal. He is also a full-time researcher at the CHU Sainte-Justine Research Center and principal investigator in regenerative medicine, organs-on-chip, and bioprinting at TransMedTech Institute. Dr. Savoji received his PhD in Biomedical Engineering from the Institute of Biomedical Engineering at Polytechnique Montréal in 2016. He then completed a postdoctoral fellowship at the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. His research expertise combines advanced manufacturing technologies (micro- and nano-fabrication, 3D bioprinting, microfluidics, cell electrospinning) with functional and composite materials for applications in tissue engineering, regenerative medicine, and organs-on-chip. His work focuses on the design, development, optimization, implementation, and characterization of innovative functional biomaterials using emerging engineering technologies, with particular emphasis on cardiac tissue engineering and biomimetic pulmonary heart valves for pediatric patients. Dr. Savoji has published extensively on biomaterials, tissue engineering, 3D bioprinting, and organ-on-chip technologies. His recent publications demonstrate expertise in viscoelastic characterization of soft tissues, engineering immune responses to biomaterials, ceramic engineering for biomedical applications, and advanced 3D bioprinting techniques for cardiac and vascular tissue engineering. 2017-2020, Postdoctoral Research Grant, CIHR 2017-2019, Postdoctoral Research Grant, FRQNT 2017-2018, Human Society of International Grant, Human Toxicity Assessment Project 2016, CR-CHUM Research Center Award 2015, Star Student-Researcher Award, FRQNT 2014-2015, Jane and Frank Warchol Fellowship, Society of Vacuum Coaters Foundation 2013, Institute of Textile Science Award 2012-2015, Excellence Doctoral Scholarship for Foreign Students, FRQNT Dr. Savoji has supervised Master's students including Ines Barrakad (2024) working on 'Advanced manufacturing technologies versus molding of corneal implants: 3D printing vs molding of a Keratoprosthesis' and Zineb Ajji (2023) researching 'Development of perfusable patches by 3D bioprinting for potential application in cardiac tissue regeneration.' He has secured numerous research grants from organizations including CIHR, NSERC, FRQNT, FRQS, MITACS, and others for projects related to 3D bioprinting of cardiac tissues, biomimetic heart valves, and other tissue engineering applications. The Savoji Laboratory, located within the Department of Pharmacology and Physiology and Institute of Biomedical Engineering of the Faculty of Medicine of the University of Montreal, the Research Center of the CHU Sainte-Justine (CHUSJ), and the TransMedTech Institute, focuses on multidisciplinary research involving 3D bioprinting using stem-cell derived human cardiac cells to fabricate functional cardiac tissues for transplantation and drug discovery applications.

• Bioengineering
• Tissue Engineering
• Regenerative Medicine
• +4 more

Sachdev Sidhu is a Research Professor and Entrepreneur in Residence at the University of Waterloo. His research focuses on synthetic antibodies, protein engineering, and biotechnological applications. He leads efforts in developing novel therapeutic antibodies, engineered protein systems, and molecular tools for biomedical research. His work spans cancer therapy, viral infection countermeasures, and regenerative medicine. Sidhu is also involved in translational research, bridging academic discoveries with commercial applications through entrepreneurial ventures. Key research interests include synthetic antibody libraries, CAR T-cell engineering, ubiquitin-based therapeutics, and phage display technologies. He has contributed to advancements in targeted therapies for glioblastoma, leukemia, and ocular diseases. His team develops innovative methods for protein design, such as engineered ubiquitin variants and modular antibody architectures. Publications highlight breakthroughs in antibody-based treatments, including synNotch CAR T cells for glioblastoma and neutralizing antibodies against SARS-CoV-2. His work integrates structural biology, molecular biology, and computational approaches to address complex biomedical challenges. Sidhu collaborates with industry partners to advance technologies into clinical and commercial settings.

• Synthetic Antibodies
• Protein Engineering
• Biotechnology
• +5 more

C. Perry Chou is a full professor in the Chemical Engineering Department at the University of Waterloo, with a cross-appointment in Biology. He holds a BSc and MSc from National Taiwan University and a PhD from Rice University, all in Chemical Engineering. His research focuses on integrating biochemical, genetic, and metabolic engineering strategies to enhance biomanufacturing using microbial cell factories. Key areas include recombinant protein production, microbial biotechnology, and biofuel development. Education: PhD in Chemical Engineering, Rice University (1995) MSc in Chemical Engineering, National Taiwan University (1987) BSc in Chemical Engineering, National Taiwan University (1984) Research Interests: Dr. Chou’s work spans biochemical engineering, bioprocessing, and metabolic engineering. He develops strategies for microbial strain construction, fermentation optimization, and bioproduct purification. His research bridges fundamental biological sciences with applied engineering to advance biomanufacturing. Publications: His 90+ peer-reviewed articles highlight contributions to strain engineering, CRISPR-Cas9 tools, and microbial production of chemicals like 5-aminolevulinic acid and propionate. Recent trends emphasize nanomaterial applications (e.g., graphene oxide) and sustainable biofuel pathways. Awards: Canada Research Chair (Canada) 1000-talent Award (China) Advising & Grants: Dr. Chou actively mentors graduate students and contributes to editorial roles at journals like Biotechnology Advances and Scientific Reports . He teaches courses such as CHE 161 (Engineering Biology) and CHE 562 (Advanced Bioprocess Engineering). Labs/Teams: Collaborates with interdisciplinary teams to advance bioprocess development, though specific lab names are not explicitly mentioned in the text.

• biochemical engineering
• bioprocessing
• biomanufacturing
• +7 more

Professor Louis Schmidt is a leading academic in the Department of Psychology, Neuroscience & Behaviour at McMaster University , with a research focus on developmental psychophysiology, temperament, and the long-term effects of early adversity. His work bridges neuroscience, psychology, and behavioral science, emphasizing the interplay between brain function and socio-emotional development across the lifespan. Key research themes: Shyness, social anxiety, autism spectrum disorder, schizophrenia, and outcomes of extremely low birth weight. Recognized for mentoring postdoctoral fellow Kristie Poole, who was celebrated as a role model in the Child Emotion Laboratory. Scientific Awards : Royal Society of Canada recognition for contributions to research and scholarship. Research Trends from 15 recent publications include: Neurophysiological mechanisms of shyness (EEG, ERP, RSA) Impact of antenatal corticosteroids on adult brain function Intergenerational effects of maternal mental health interventions Cross-cultural comparisons of temperamental shyness Developmental consequences of preterm birth Behavioral and neural correlates of social anxiety in diverse populations Grants & Collaborations : Led the SNACS randomized controlled trial on antenatal corticosteroids, with applications in obstetrics and developmental neuroscience. Collaborates extensively on topics like autism spectrum disorder, schizophrenia, and emotion regulation. Labs & Teams : Directs the Child Emotion Laboratory at McMaster University, fostering interdisciplinary research on developmental psychopathology and neural mechanisms of temperament.

• Developmental Psychophysiology
• Temperament and Personality Development
• Neuroscience of Shyness and Social Anxiety
• +4 more

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +13 more

Elisabeth Prince is an Assistant Professor at the University of Waterloo, specializing in polymer chemistry and biomaterials. Her research focuses on developing advanced materials for biomedical applications, sustainable materials, and microfluidic technologies. Key areas include conductive hydrogels, cleavable polymers for recyclability, and biomimetic systems for drug delivery and cancer therapy. Her work bridges disciplines such as materials science, nanotechnology, and biomedical engineering. Recent studies involve applications in strain-stiffening hydrogels, filamentous aerogels for electromagnetic shielding, and microfluidic platforms for organoid production. These innovations aim to address challenges in regenerative medicine, environmental sustainability, and personalized cancer treatments. No scientific awards are listed in the provided materials. Research activities include collaborations on 3D-printed microfluidic devices and nanofibrillar hydrogels mimicking biological systems. No advising relationships or grants are explicitly mentioned in the text.

• Polymer Chemistry
• Biomedical Engineering
• Materials Science
• +7 more

Dr. Channakeshava S. Umeshappa is a faculty member in the Department of Microbiology & Immunology and Department of Pediatrics at Dalhousie University, Canada . He holds a PhD in Immunology from the University of Saskatchewan and completed postdoctoral training at the University of Calgary. Education : DVM (Karnataka Veterinary Animal and Fisheries Sciences University, India), MVSc (Indian Veterinary Research Institute, India), PhD (University of Saskatchewan, Canada) Research Interests : Dr. Umeshappa’s program focuses on immunoregulation in chronic diseases , particularly autoimmunity and cancer. His lab employs genetically modified murine models , omics , synthetic biology , flow cytometry , and imaging to develop immunotherapies. His work emphasizes interdisciplinary collaboration with clinicians and scientists. Article Trends : Recent publications highlight nanomedicine applications in autoimmune liver disease (e.g., peptide-MHC nanomedicines, invariant NKT cell reprogramming) and cancer therapy (e.g., laser-responsive nanoparticles, tumor-to-lymph gels). Studies span immuno-informatics , cell signaling , and clinical outcomes analysis.

• Human Immunology
• Inflammation
• Autoimmunity
• +3 more

Orlando Rojas is a Professor at the University of British Columbia (UBC), holding joint appointments in the Departments of Chemical and Biological Engineering, Chemistry, and Wood Science. He leads the Biobased Colloids and Materials (BiCMat) research group and directs the Bioproducts Institute . His research focuses on sustainable development through renewable materials, including nanopolysaccharides, bacterial nanocellulose, lignins, and multiphase systems. Rojas has advised over 50 PhD students and 40+ MS students, with a h-index of 90 (Google Scholar). Key Roles/Positions : Canada Excellence Research Chair in Renewable Materials Adjunct Professor at NC State University (USA) and Dalian Polytechnic University (China) Director of FinnCERES Flagship (Finland) Research Interests : Development of bio-based materials for energy, healthcare, and environmental applications. Key areas include nanocellulose functionalization, lignin valorization, and bioinspired materials. His work integrates colloidal science, multiphase systems, and sustainable manufacturing. Grants & Awards : ERC Advanced Grant and Horizon H2020 funding 2013 ACS Fellow, 2015 Tappi Nanotechnology Award First Latin-American recipient of the Anselme Payen Award (ACS) Labs & Collaborations : Active partnerships with Aalto University (Finland) and institutions globally. Leads the BiCMat group spanning UBC and FinnCERES, focusing on bio-based materials and sustainable technologies.

• Renewable Materials
• Biopolymers
• Nanocellulose
• +7 more

Professor Hanadi Sleiman is a renowned academic in the Department of Chemistry at McGill University, specializing in DNA-based nanomaterials and their applications in drug delivery and supramolecular chemistry. She holds leadership roles, including Director of the NSERC CREATE training program in Nucleic Acids and President of the International DNA Nanotechnology Society (ISNSCE). Her research focuses on engineering DNA nanostructures for targeted therapies, such as cancer treatments, and advancing materials chemistry through DNA-functionalized systems. Education: Ph.D. in Chemistry, Stanford University (1990) Postdoctoral Fellow, University of Louis Pasteur (1993) Research Interests: Professor Sleiman’s work combines synthetic chemistry with DNA self-assembly to create programmable materials. Her lab designs DNA cages for drug encapsulation, explores DNA-minimal approaches to scalable materials, and integrates DNA with nanoparticles, polymers, and metals for biomedical applications. Key areas include cancer therapy, biosensors, and enzyme mimics. Awards & Honors: Fellow of the Royal Society of Canada (2017) Killam Research Fellowship (2018) R. U. Lemieux Award in Organic Chemistry (2018) William Dawson Scholar Award (2004–2012) Grants & Collaborations: She directs the NSERC CREATE program and collaborates with institutions like the Quebec Centre for Advanced Materials (QCAM) and the McGill Centre for Structural Biology (CRBS). Her training initiatives emphasize nucleic acid therapeutics and diagnostics. Labs & Teams: Her Sleiman Group at McGill develops innovative DNA architectures in the Otto Maass laboratory, with a focus on translational research for clinical applications.

• Chemical Biology
• Materials Chemistry
• Nanotechnology
• +3 more

John Capobianco, PhD, is a Professor in the Department of Chemistry and Biochemistry at Concordia University and holds the Honorary Concordia University Research Chair in Nanoscience. His research focuses on lanthanide-doped nanoparticles, upconversion luminescence, and biomedical applications. PhD, University of Geneva Key research areas include: Nanomaterials synthesis and spectroscopy Upconversion for biomedical imaging Drug delivery systems Photodynamic therapy for cancer treatment Optical thermometry and sensing Recent publications highlight advancements in: X-ray detection via photochromic nanoparticles Lipid-coated nanoparticles for lung permeation Cooperative energy transfer in Yb3+/Eu3+ complexes Biocompatible nanomaterials for secure information storage Pr3+-doped radiosensitizers for glioblastoma therapy Scientific recognitions: Honorary Concordia University Research Chair in Nanoscience Teaching includes undergraduate and graduate courses in inorganic chemistry and spectroscopy. His work bridges fundamental material science with applied biomedical engineering, emphasizing optical properties and therapeutic applications of lanthanide-based nanomaterials.

• Nanoscience
• Inorganic Chemistry
• Materials Science
• +7 more

John F Valliant is a Professor in the Department of Chemistry and Chemical Biology at McMaster University. His research focuses on radiopharmaceutical chemistry, molecular imaging, and targeted therapies, particularly in cancer diagnostics and therapeutics. He co-founded Fusion Pharmaceuticals, a company acquired by AstraZeneca for $2.4 billion (US), which specializes in targeted alpha therapy for cancer treatment. His work includes developing radiolabeled imaging agents for prostate cancer (e.g., [18F]DCFPyL), targeted alpha therapies (e.g., FPI-1434), and bioorthogonal chemistry strategies for pretargeted imaging. Valliant has contributed to advancements in photoacoustic imaging, SPECT/PET modalities, and theranostic agents for conditions like bacterial infections and bone diseases. Key projects include the Phase II clinical trial using 18F-DCFPyL PET-MRI for oligometastatic prostate cancer and studies on individualized dosimetry in Lu-177 therapies. He has pioneered platforms for radiolabeled antibody-recruiting molecules and fluorous-phase chemistry for high-specific-activity probes. Valliant’s research bridges disciplines, integrating chemistry, biology, and clinical applications to address unmet medical needs in oncology and diagnostic imaging.

• Radiopharmaceutical Chemistry
• Nuclear Medicine
• Molecular Imaging
• +5 more